Benjamin P. Saylor
Saylor is content managing editor for Urology Times.
Physician work force advocate Dr. Cooper remembered
Richard “Buz” Cooper, MD, an outspoken figure on health care work force shortages, dies at 79.
Uro Pipeline: 1st patients treated in phase III study of investigational BPH Tx
Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.
MOC, ICD-10 among hot urology topics of 2015
Look back on the year that was with this roundup of the 10 most-read Urology Times articles from 2015.
What’s on your colleagues’ wish lists for 2016
We asked members of our editorial board what they hope to see in the world of urology in the coming year.
Uro Pipeline: Phase III data show drug’s benefit in castrate-resistant PCa
Other pipeline products discussed in this article include agents for urinary catheter blockage, prostate cancer, bladder cancer, and overactive bladder.
Uro Pipeline: IDE approval granted for implantable neurostimulator
A prostate cancer vaccine and an infertility diagnostic tool are among the other pipeline products discussed in this round-up.
Botulinum efficacious long term for neurogenic bladder
OnabotulinumtoxinA (Botox) appears to offer long-term benefits in patients with neurogenic detrusor overactivity, recent study results indicate.
Dr. Gonzalez named urology chair at Case
In other personnel news, Thomas Jefferson’s Sidney Kimmel Cancer Center has a new director and LUGPA has its first CEO.
NPPs in urology by the numbers
Exclusive data from our State of the Specialty survey reveals the growing importance of non-physician providers in the urology work force.
Immunotherapy shows survival benefit in advanced RCC
An immune checkpoint inhibitor provides “a real opportunity to change clinical practice” for patients with metastatic renal cell carcinoma, a study author says.